2. Cancer
  3. Cancer Targeted Therapy

Cancer Targeted Therapy

Cancer targeted therapy is the foundation of precision medicine; it uses drugs or other substances to target specific genes and proteins that control cancer cells’ growth, division and spreading. Compared to traditional chemotherapy drugs, targeted-drugs can specifically act on cancer cells with high efficacy without damaging normal cells. Drugs used in cancer targeted therapy mainly includes small molecules and macromolecules (e.g., monoclonal antibodies), which can target cancer cells and constituents in the tumor microenvironment to activate the immune system. Anti-angiogenesis drugs, such as those targeting vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), transforming growth factor (TGF)-α, TGF-β, Tumor necrosis factor (TNF)-α, and platelet-derived endothelial growth factor (PDGFR) inhibit the proliferation and metastasis of cancer cells. In recent years, the proportion of antibody drugs in cancer treatment has gradually become prominent. Antibody-drug conjugates (ADCs) are a new type of targeted drugs that are composed of monoclonal antibody, cytotoxic drug and linker. ADCs can deliver drugs to tumor cells and minimize the toxicity to normal tissues. Proteolysis-targeting chimera (PROTAC) is a useful technology for targeted protein degradation. PROTAC exploits the ubiquitin-proteasome system and forms a ternary complex with a hijacked E3 ubiquitin ligase and target protein, leading to polyubiquitination and degradation of the target protein.

Targeted therapy is a useful strategy in treatment of cancer either alone or in combination with standard chemotherapy. At present, targeted therapy has proved significant clinical success in the treatment of many types of cancer, including breast cancer, colorectal cancer, leukemia, ovarian cancer and lung cancer.

Cancer Targeted Therapy Related Products (35769):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W017440R
    Triethylene glycol (Standard) 112-27-6
    Triethylene glycol (Standard) is the analytical standard of Triethylene glycol. This product is intended for research and analytical applications. Triethylene glycol (PROTAC Linker 25) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
    Triethylene glycol (Standard)
  • HY-RI00635
    hsa-miR-3178 inhibitor
    hsa-miR-3178 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-3178 inhibitor
  • HY-116349
    Bromodomain IN-1 1914120-48-1
    Bromodomain IN-1 is a Bromodomain inhibitor extracted from patent WO2016069578A1, compound 4 .
    Bromodomain IN-1
  • HY-170826
    SMARCA2 ligand-14
    SMARCA2 ligand-14 is the ligand for SMARCA2 that can be used for synthesis of PROTAC degrader SMD-3236 (HY-170824).
    SMARCA2 ligand-14
  • HY-RI03897
    mmu-miR-7076-3p inhibitor
    mmu-miR-7076-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    mmu-miR-7076-3p inhibitor
  • HY-RI01227
    hsa-miR-4666a-3p inhibitor
    hsa-miR-4666a-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-4666a-3p inhibitor
  • HY-RI01911A
    hsa-miR-637 antagomir
    hsa-miR-637 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-637 antagomir
  • HY-136060
    Mal-PEG2-bis-PEG3-BCN
    Mal-PEG2-bis-PEG3-BCN is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG2-bis-PEG3-BCN is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    Mal-PEG2-bis-PEG3-BCN
  • HY-157443
    Myt1-IN-4
    Myt1-IN-4 (21) is an orally active and selective membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor, with an IC50 of 2.6 nM. Myt1-IN-4 (21) possesses antitumor activity.
    Myt1-IN-4
  • HY-117651R
    2-Fluoropalmitic acid (Standard) 16518-94-8
    Quinine (sulfate hydrate) (Standard) is the analytical standard of Quinine (sulfate hydrate). This product is intended for research and analytical applications. Quinine sulfate hydrate (2:1:4) is an orally active alkaloid extracted from cinchona bark and can be used in anti-malarial studies. Quinine sulfate hydrate (2:1:4) is a potassium channel inhibitor that inhibits WT mouse Slo3 (KCa5.1) channel currents evoked by voltage pulses to +100?mV with an IC50 of 169 μM.
    2-Fluoropalmitic acid (Standard)
  • HY-RI04546
    rno-miR-6334 inhibitor
    rno-miR-6334 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    rno-miR-6334 inhibitor
  • HY-RI00335
    hsa-miR-181d-3p inhibitor
    hsa-miR-181d-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-181d-3p inhibitor
  • HY-163591
    PRMT5-IN-36-d3 3034034-10-8
    PRMT5-IN-36-d3 is the deuterated derivative of PRMT5-IN-36. PRMT5-IN-36-d3 (compound 4) is an orally active PRMT5 inhibitor for cancer research.
    PRMT5-IN-36-d<sub>3</sub>
  • HY-163740
    VEGFR-2-IN-46
    VEGFR-2-IN-46 (compound 4d) is a potent VEGFR-2 inhibitor with an EC50 value of 67.0 nM. VEGFR-2-IN-46 shows cytotoxicity and induces cell cycle arrest at the G2/M phase. VEGFR-2-IN-46 induces necrosis and apoptosis.
    VEGFR-2-IN-46
  • HY-RI02111
    hsa-miR-6774-5p inhibitor
    hsa-miR-6774-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-6774-5p inhibitor
  • HY-120571
    L-674573 127481-29-2 99.54%
    L-674573 is a quinoline leukotriene synthesis inhibitor, inhibiting Calcimycin (HY-N6687)- and N-Formyl-Met-Leu-Phe (HY-P0224)-induced leukotriene production with IC50s of 100 nM and 50 nM, respectively. L-674573 selectively inhibits Calcimycin- and N-Formyl-Met-Leu-Phe-induced 5-lipoxygenase translocation.
    L-674573
  • HY-RI01752A
    hsa-miR-561-5p antagomir
    hsa-miR-561-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-561-5p antagomir
  • HY-157006
    (S)-TCO-PEG3-NH2
    (S)-TCO-PEG3-NH2 is an ADC linker containing 3 PEG units. (S)-TCO-PEG3-NH2 can use its own TCO group to perform the inverse electron demand Diels-Alder reaction (iEDDA) with molecules with Tetrazine groups.
    (S)-TCO-PEG3-NH2
  • HY-151443
    HDAC-IN-47
    HDAC-IN-47 is an orally active inhibitor of histone deacetylase (HDAC), with IC50s of 19.75 nM (HDAC1), 5.63 nM (HDAC2), 40.27 nM (HDAC3), 57.8 nM (HDAC2), 302.73 nM (HDAC8), respectively. HDAC-IN-47 inhibits autophagy and induces apoptosis via the Bax/Bcl-2 and caspase-3 pathways. HDAC-IN-47 arrests cell cycle at G2/M phase, and shows anti-tumor efficacy in vivo.
    HDAC-IN-47
  • HY-RI02066A
    hsa-miR-6754-5p antagomir
    hsa-miR-6754-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-6754-5p antagomir